Novo Nordisk A/S $NVO Shares Bought by Mengis Capital Management Inc.

Mengis Capital Management Inc. boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 303.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,694 shares of the company’s stock after buying an additional 50,154 shares during the quarter. Mengis Capital Management Inc.’s holdings in Novo Nordisk A/S were worth $3,393,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in NVO. Smith Chas P & Associates PA Cpas grew its stake in shares of Novo Nordisk A/S by 105.3% in the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock valued at $22,497,000 after buying an additional 207,959 shares in the last quarter. Clifford Swan Investment Counsel LLC lifted its stake in Novo Nordisk A/S by 13.7% during the 3rd quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock worth $17,267,000 after acquiring an additional 37,453 shares in the last quarter. Quantbot Technologies LP purchased a new position in Novo Nordisk A/S during the 3rd quarter valued at about $3,171,000. CIBC Bancorp USA Inc. acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at about $19,519,000. Finally, Romano Brothers AND Company grew its position in Novo Nordisk A/S by 704.0% in the 4th quarter. Romano Brothers AND Company now owns 34,236 shares of the company’s stock valued at $1,742,000 after acquiring an additional 29,978 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $43.20 on Friday. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $74.38. The company has a market cap of $192.89 billion, a PE ratio of 10.14, a P/E/G ratio of 3.86 and a beta of 0.78. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The business has a 50-day simple moving average of $42.92 and a 200-day simple moving average of $45.85.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The firm had revenue of $10.85 billion for the quarter. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NVO has been the topic of several research reports. Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target on the stock in a research report on Tuesday, March 3rd. Wolfe Research began coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating for the company. Sanford C. Bernstein assumed coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 target price on the stock. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Five research analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.